Cannabidiol nanotherapeutics - Aphios Corporation
Alternative Names: APH-1403Latest Information Update: 25 Nov 2021
Price :
$50 *
At a glance
- Originator Aphios Corporation; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
- Developer Aphios Corporation
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 agonists; Cannabinoid receptor CB2 inverse agonists; Peroxisome proliferator-activated receptor gamma agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Epilepsy; Multiple sclerosis
Most Recent Events
- 25 Nov 2021 Discontinued for Epilepsy in USA (PO) in November 2021 (Aphios Corporation pipeline, November 2021)
- 25 Nov 2021 Discontinued for Multiple sclerosis in USA (PO) in November 2021 (Aphios Corporation pipeline, November 2021)
- 01 Apr 2021 Cannabidiol nanotherapeutics is available for licensing as of 01 Apr 2021. https://aphios.com/products/therapeutic-products-pipeline/cns-disorders/aph-1403/